• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    46 Stocks Moving In Thursday's Mid-Day Session

    1/27/22 12:11:12 PM ET
    $ARAY
    $BLL
    $BSFC
    $CCAC
    Medical/Dental Instruments
    Health Care
    Containers/Packaging
    Consumer Durables
    Get the next $ARAY alert in real time by email

    Gainers

    • Indonesia Energy Corporation Limited (NASDAQ:INDO) shares jumped 158.2% to $7.23 after tumbling 18% on Wednesday. Indonesia Energy said it projects to commence drilling of 2 back-to-back new wells within 30 days and a third by mid-year.
    • The National Security Group, Inc. (NASDAQ:NSEC) shares jumped 73.2% to $15.59 after VR Insurance announced acquisition of the company.
    • Save Foods, Inc. (NASDAQ:SVFD) surged 27% to $4.58 after the company said it is extending the range of applications of its eco crop protection treatment after successfully applying it to fresh berries in a recent trial.
    • Seagate Technology Holdings plc (NASDAQ:STX) gained 18.5% to $114.08 after the company reported better-than-expected Q2 results and issued guidance.
    • Marine Petroleum Trust (NASDAQ:MARPS) jumped 18.1% to $5.21.
    • Galapagos NV (NASDAQ:GLPG) shares gained 18% to $62.94. Galapagos announced the appointment of Dr. Paul Stoffels as chief executive officer, effective April 1, 2022. Previously, Stoffels was vice chairman of the executive committee and chief scientific officer of Johnson & Johnson, where he spearheaded the company's research and product pipeline.
    • SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) gained 17.3% to $5.96. China's National Medical Products Administration (NMPA) signed off SELLAS Life Sciences Group’s IND application to initiate the first clinical trial for 3D189 in patients with hematological malignancies.
    • New Concept Energy, Inc. (NYSE:GBR) rose 17% to $3.0320.
    • Farmmi, Inc. (NASDAQ:FAMI) shares gained 14.7% to $0.2269. Farmmi reported FY21 sales of $39.29 million up from $28.36 million in the year-ago period.
    • LSI Industries Inc. (NASDAQ:LYTS) jumped 13.2% to $6.79 following upbeat Q2 earnings.
    • ServiceNow, Inc. (NYSE:NOW) rose 12.5% to $544.74 after the company reported better-than-expected Q4 results.
    • Dogness (International) Corporation (NASDAQ:DOGZ) gained 12.3% to $3.8850.
    • DouYu International Holdings Limited (NASDAQ:DOYU) rose 12% to $2.4750. Tencent Holdings is looking to take DouYu International private by 2022 end amid disagreements over strategy among executives at the Chinese videogame streaming firm, Reuters reported.
    • Mechel PAO (NYSE:MTL) rose 11.6% to $2.80 after declining around 5% on Wednesday.
    • Levi Strauss & Co. (NYSE:LEVI) rose 10.2% to $22.40 after the company reported Q4 results and issued FY22 forecast.
    • TSR, Inc. (NASDAQ:TSRI) gained 10% to $13.09.
    • Qualtrics International Inc. (NASDAQ:XM) rose 9.7% to $26.60 after the company reported better-than-expected Q4 sales results and issued guidance.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) gained 9.3% to $3.88. Immix Biopharma’s IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system.
    • Packaging Corporation of America (NYSE:PKG) surged 9.2% to $145.68. Packaging Corp Of America reported fourth-quarter FY21 sales growth of 19% year-on-year, to $2.04 billion, beating the analyst consensus of $1.94 billion.
    • Celestica Inc. (NYSE:CLS) gained 7.6% to $11.80 following upbeat Q4 results.
    • Ball Corporation (NYSE:BLL) gained 6.6% to $92.26 after reporting better-than-expected quarterly results.
    • Mainz Biomed B.V. (NASDAQ:MYNZ) rose 5.7% to $15.32. Mainz Biomed shares dipped 28% on Wednesday after the company priced a 1.5 million share follow-on offering at $15 per share.
    • Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) rose 5% to $6.73. Baird initiated coverage on Reneo Pharmaceuticals with an Outperform rating and announced price target of $28.

    Check out these penny stocks insiders are buying

    Losers

    • Epizyme, Inc. (NASDAQ:EPZM) shares fell 36.1% to $1.2150 after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts.
    • 1-800-FLOWERS.COM, Inc. (NASDAQ:FLWS) shares dipped 31% to $14.60 after the company reported worse-than-expected Q2 EPS and sales results. 1-800-Flowers sees FY22 revenue growth of 7% - 9%.
    • Teradyne, Inc. (NASDAQ:TER) fell 28% to $103.38 after the company issued Q1 EPS and sales guidance below estimates.
    • LendingClub Corporation (NYSE:LC) fell 25.4% to $16.78 after the company reported Q4 earnings results and issued Q1 and FY22 sales guidance. Credit Suisse maintained LendingClub with a Neutral and lowered the price target from $34 to $27.
    • Merida Merger Corp. I (NASDAQ:MCMJ) dropped 23.6% to $7.63.
    • Blue Star Foods Corp. (NASDAQ:BSFC) fell 22.7% to $2.93. Blue Star Foods recently said it will receive $5 million investment from The Lind Partners.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) fell 22% to $10.83. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL.
    • Cue Biopharma, Inc. (NASDAQ:CUE) dropped 20.4% to $8.44. Cue Biopharma said early data from the Phase 1 combination study of CUE-101 and Merck & Co., supported synergistic activity, with two of the four patients treated in dose escalation in two cohosts showing partial responses.
    • Ivanhoe Capital Acquisition Corp. (NYSE:IVAN) dropped 19.1% to $8.07.
    • Accuray Incorporated (NASDAQ:ARAY) fell 15.6% to $3.4350 following Q2 results.
    • Ebang International Holdings Inc. (NASDAQ:EBON) fell 14.3% to $0.9343 after jumping 35% on Wednesday.
    • Weidai Ltd. (NYSE:WEI) fell 13.7% to $2.0177.
    • Yoshitsu Co., Ltd (NASDAQ:TKLF) dropped 13.7% to $2.81.
    • CITIC Capital Acquisition Corp. (NYSE:CCAC) declined 12.1% to $8.72.
    • Unifi, Inc. (NYSE:UFI) fell 11.5% to $19.86 following Q2 earnings.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) dropped 11.3% to $3.69. B of A Securities recently initiated coverage on Pear Therapeutics with a Neutral rating and announced a price target of $5.
    • Watts Water Technologies, Inc. (NYSE:WTS) fell 10.3% to $152.33. Watts Water Technologies will replace Sterling Bancorp/DE in the S&P MidCap 400.
    • Tesla, Inc. (NASDAQ:TSLA) fell 7.9% to $863.56. Tesla reported better-than-expected earnings and sales results for its fourth quarter. The company produced 305,840 vehicles in the fourth quarter, up 70% year-over-year. A total of 308,650 vehicles were delivered in the fourth quarter, up 71% year-over-year.
    • Haemonetics Corporation (NYSE:HAE) dropped 7.7% to $43.75. Needham downgraded Haemonetics from Buy to Hold.
    • LG Display Co., Ltd. (NYSE:LPL) fell 7.5% to $8.14. LG Display recently reported fourth-quarter FY21 revenue growth of 18% year-on-year to KRW 8.81 trillion.
    • Intel Corporation (NASDAQ:INTC) dipped 7.1% to $48.01 after the company issued Q1 EPS guidance below estimates.
    • SAP SE (NYSE:SAP) fell 6.7% to $123.43. SAP reported fourth-quarter FY21 revenue growth of 3% year-on-year to €7.98 billion at constant currencies and announced plans to acquire a majority stake of Taulia, a leading provider of working capital management solutions.
    • Zymeworks Inc. (NASDAQ:ZYME) shares fell 5.6% to $8.81 after the company reported pricing of $100.0 million public offering.

    Also check out insider selling in big stocks

    Get the next $ARAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY
    $BLL
    $BSFC
    $CCAC

    CompanyDatePrice TargetRatingAnalyst
    Levi Strauss & Co
    $LEVI
    2/4/2026$25.00Buy
    Jefferies
    Teradyne Inc.
    $TER
    2/4/2026$270.00Outperform → Market Perform
    Northland Capital
    SAP SE
    $SAP
    2/3/2026Overweight
    Piper Sandler
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    SAP SE
    $SAP
    1/30/2026Mkt Outperform → Mkt Perform
    Citizens JMP
    ServiceNow Inc.
    $NOW
    1/29/2026$175.00 → $170.00Outperform
    BMO Capital Markets
    Celestica Inc.
    $CLS
    1/28/2026$400.00Buy
    BofA Securities
    Seagate Technology Holdings PLC
    $STX
    1/28/2026$340.00 → $500.00Buy
    TD Cowen
    More analyst ratings

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO Zinsner David bought $249,985 worth of shares (5,882 units at $42.50), increasing direct ownership by 2% to 247,392 units (SEC Form 4)

    4 - INTEL CORP (0000050863) (Issuer)

    1/27/26 4:28:29 PM ET
    $INTC
    Semiconductors
    Technology

    Amendment: Large owner Donahue Kevin Michael bought $1,034,350 worth of shares (685,000 units at $1.51) (SEC Form 4)

    4/A - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/20/26 10:29:36 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Donahue Kevin Michael bought $258,827,700,000 worth of shares (643,850 units at $402,000.00) (SEC Form 4)

    4 - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/16/26 3:42:37 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Levi Strauss with a new price target

    Jefferies initiated coverage of Levi Strauss with a rating of Buy and set a new price target of $25.00

    2/4/26 8:29:42 AM ET
    $LEVI
    Apparel
    Consumer Discretionary

    Teradyne downgraded by Northland Capital with a new price target

    Northland Capital downgraded Teradyne from Outperform to Market Perform and set a new price target of $270.00

    2/4/26 8:20:32 AM ET
    $TER
    Electrical Products
    Industrials

    Piper Sandler resumed coverage on SAP SE

    Piper Sandler resumed coverage of SAP SE with a rating of Overweight

    2/3/26 6:56:53 AM ET
    $SAP
    Computer Software: Prepackaged Software
    Technology

    $ARAY
    $BLL
    $BSFC
    $CCAC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TAZVERIK issued to EPIZYME INC

    Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

    8/14/24 4:43:30 AM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TAZVERIK issued to EPIZYME INC

    Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-4) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 11/16/2023. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

    11/17/23 4:37:35 AM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Smith Gregory Stephen was granted 13,380 shares, increasing direct ownership by 12% to 128,470 units (SEC Form 4)

    4 - TERADYNE, INC (0000097210) (Issuer)

    2/6/26 5:15:43 PM ET
    $TER
    Electrical Products
    Industrials

    President, Semiconductor Test Poulin Shannon John was granted 4,460 shares, increasing direct ownership by 35% to 17,236 units (SEC Form 4)

    4 - TERADYNE, INC (0000097210) (Issuer)

    2/6/26 5:08:50 PM ET
    $TER
    Electrical Products
    Industrials

    VP, General Counsel, Secretary Driscoll Ryan was granted 1,784 shares, increasing direct ownership by 27% to 8,345 units (SEC Form 4)

    4 - TERADYNE, INC (0000097210) (Issuer)

    2/6/26 5:03:27 PM ET
    $TER
    Electrical Products
    Industrials

    $ARAY
    $BLL
    $BSFC
    $CCAC
    SEC Filings

    View All

    Accuray Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    2/6/26 4:05:57 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Indonesia Energy Corporation Limited

    424B5 - Indonesia Energy Corp Ltd (0001757840) (Filer)

    2/5/26 4:08:40 PM ET
    $INDO
    Oil & Gas Production
    Energy

    Amendment: SEC Form SCHEDULE 13G/A filed by Celestica Inc.

    SCHEDULE 13G/A - CELESTICA INC (0001030894) (Subject)

    2/5/26 1:20:38 PM ET
    $CLS
    Electrical Products
    Technology

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

    A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced a collaboration with actress Christina Applegate to help raise awareness of multiple sclerosis (MS) and support meaningful conversations for those living with the disease. Christina Applegate, who has been living with MS for 5 years, will lead the new national disease-awareness initiative designed to elevate the voices of people living with MS, highlight the realities, and explore what comes next, on their own terms. The cornerstone of the campaign is www.NextInMS.com, a new platform developed to support p

    2/8/26 4:17:55 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting, including updates from the ENABLE real world study evaluating patients with RMS on BRIUMVI. Our presentations reflect our continued focus on advancing the clinical understanding of

    2/6/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BetterInvesting™ Magazine Update on ServiceNow Inc. (NYSE: NOW) and Deckers Outdoors Corp. (NYSE: DECK)

    TROY, Mich., Feb. 6, 2026 /PRNewswire/ -- ServiceNow Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers ServiceNow (NYSE:NOW) as worthy of further study and has named the company its "Stock to Study" for the April 2026 issue for investors' informational and educational use. The fundamental data is eye-opening; investors can view ServiceNow's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at:  https://ssg.betterinvesting.org/trial/ssgplus/?ticke

    2/6/26 7:29:00 AM ET
    $DECK
    $NOW
    Shoe Manufacturing
    Consumer Discretionary
    Computer Software: Prepackaged Software
    Technology

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Leadership Updates

    Live Leadership Updates

    View All

    ServiceNow appoints Hossein Nowbar as President and CLO

    ServiceNow (NYSE NOW), the AI control tower for business reinvention, today announced that Hossein Nowbar has joined the company as President and Chief Legal Officer (CLO). Russ Elmer, who has served as Chief Legal Officer since 2018, will transition to the role of Special Counsel, where he will continue to provide strategic guidance and ensure continuity on key legal and corporate matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105439880/en/ Most recently serving as Chief Legal Officer and Corporate Vice President at Microsoft Corporation, Nowbar brings extensive experience shaping policy priorities, fostering public

    1/5/26 1:00:00 PM ET
    $NOW
    Computer Software: Prepackaged Software
    Technology

    Levi Strauss & Co. Appoints Jeffrey J. Jones II to Board of Directors

    Levi Strauss & Co. (LS&Co.) (NYSE:LEVI) announced today that its board of directors has appointed Jeffrey J. Jones II to serve as a member of the board, effective January 21, 2026, at which time he'll serve as a member of the board's Nominating, Governance and Corporate Citizenship Committee as well as the Compensation and Human Capital Committee. Mr. Jones has served as President and CEO and Director of H&R Block, Inc. (NYSE:HRB) since 2017 and brings more than 30 years of experience across five industries. "Mr. Jones brings extensive experience in consumer insights, brand building and organizational transformation and has a proven record of creating significant stakeholder value," said B

    12/16/25 5:00:00 PM ET
    $HRB
    $LEVI
    Other Consumer Services
    Consumer Discretionary
    Apparel

    1-800-FLOWERS.COM, Inc. Appoints Alex Zelikovsky as Chief Information Officer

    Seasoned Technology Executive to Drive AI, Digital Commerce, and Cybersecurity Innovation JERICHO, N.Y., Dec. 8, 2025 /PRNewswire/ -- Today, 1-800-FLOWERS.COM, Inc. (NASDAQ:FLWS), a leading provider of thoughtful expressions designed to help inspire customers to express and connect, announced the appointment of Alexander Zelikovsky as Chief Information Officer. Zelikovsky's appointment accelerates the company's ongoing transformation strategy under CEO Adolfo Villagomez.  As Chief Information Officer, Zelikovsky will lead an enterprise-wide technology strategy to accelerate th

    12/8/25 8:00:00 AM ET
    $FLWS
    Other Specialty Stores
    Consumer Discretionary

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Financials

    Live finance-specific insights

    View All

    Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

    Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026. Conference Call and Webcast Information: Registration: Click here to register. Upon registra

    2/5/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    UNIFI®, Makers of REPREVE®, Announces Second Quarter Fiscal 2026 Results

    Strategic initiatives to realign cost and operational profiles have significantly reduced revenue breakeven point, while strengthening the balance sheet and financial results Unifi, Inc. (NYSE:UFI), the makers of REPREVE® and one of the world's leading innovators in recycled and synthetic yarns, today released operating results for the second fiscal quarter ended December 28, 2025. Second Quarter Fiscal 2026 Overview Cost and footprint reductions completed, and allow for an improved profitability profile at lower revenue levels going forward. Cash provided by operating activities was $25.3 million during the second quarter of fiscal 2026 and $16.4 million during the six months end

    2/3/26 4:15:00 PM ET
    $UFI
    Textiles
    Consumer Discretionary

    $ARAY
    $BLL
    $BSFC
    $CCAC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care